JP2013063926A - ドラッグデリバリー用のキャリア化合物、当該キャリア化合物が薬剤を内包する脂質膜に結合した薬剤、及び、当該薬剤を用いたドラッグデリバリーシステム - Google Patents
ドラッグデリバリー用のキャリア化合物、当該キャリア化合物が薬剤を内包する脂質膜に結合した薬剤、及び、当該薬剤を用いたドラッグデリバリーシステム Download PDFInfo
- Publication number
- JP2013063926A JP2013063926A JP2011203497A JP2011203497A JP2013063926A JP 2013063926 A JP2013063926 A JP 2013063926A JP 2011203497 A JP2011203497 A JP 2011203497A JP 2011203497 A JP2011203497 A JP 2011203497A JP 2013063926 A JP2013063926 A JP 2013063926A
- Authority
- JP
- Japan
- Prior art keywords
- drug
- drug delivery
- carrier compound
- lipid membrane
- bound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KXMMTHCAUCFZDI-UHFFFAOYSA-N CC(CCC(Cl)=O)=O Chemical compound CC(CCC(Cl)=O)=O KXMMTHCAUCFZDI-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
ドラッグデリバリーシステムにおけるリポソームの利用率を実質的に向上させるキャリア化合物を提供する。
【解決手段】本発明は、内部に薬物を有する脂質膜に親和性を有する第1の領域と、前記第1の領域と結合し、そして、自己磁性有機分子を含む第2領域と、を有するドラッグデリバリー用キャリア化合物を提供する。
【選択図】なし
Description
(リポソームの製造)
抗癌剤を内包したリポソームの製造に必要な脂質を、“Prodrugs Formings High Drug loading Mulutifunctional Nanocapsules for Intracellular cancer Drug Delivery ” J Am Chem Soc.132(2010)4259-4265を参照して製造した。
先ず、ポリエチル・グルコール・モノメチル・エステル(5.50g 10mmol)を無水テトラヒドロフラン20mlに溶解した。その得られた溶液を摂氏−20度に冷却した後、ナトリウム水素化物(0.3g 12mmol)を撹拌しながら冷却溶液に添加した。30分後、得られたポリエチレングリコールに、無水テトラヒドロフラン20mlに溶解した塩化スクシニル(1.55g 10mmol)を添加した。
がん細胞であるPOS−1細胞を24穴プレートに1.0×104/wellに適用して培養した。培養24時間後に上記で合成したリポソーム―キャリア(金属サレン錯体化合物)複合体の濃度を換え投与した。24時間後に細胞回収し、細胞生存アッセイ用のMTT試薬を投与し、45分後に0.04mol/HCl/イソプロピルアルコールを400μl加え、96穴プレートへ100μl分注し、570nmの吸光度を測定し、生存細胞率を計算した。その結果、コントロールでは、細胞生存率は100%であっが、リポソーム―キャリア化合物の複合体の濃度(10μM)程度から癌細胞殺傷効果が増大し、抗癌作用が認められることがわかった。
Claims (8)
- 内部に薬物を有する脂質膜に親和性を有する第1の領域と、前記第1の領域と結合し、そして、自己磁性有機分子を含む第2領域と、を有するドラッグデリバリー用キャリア化合物。
- 前記脂質膜はリポソームである、請求項1記載のドラッグデリバリー用キャリア化合物。
- 前記第1の領域は親水性分子を含む、請求項1記載のドラッグデリバリー用キャリア化合物。
- 前記親水性分子は、ポリエチレングリコール、タンパク質、オリゴヌクレオチド、ポリペプチド、ポリアミド、オリゴヌクレオチド、多糖類、グリコール酸、そして、乳酸の少なくとも一つである、請求項3記載のドラッグデリバリー用キャリア化合物。
- 前記自己磁性有機分子は金属サレン錯体化合物からなる、請求項1記載のドラッグデリバリー用キャリア化合物。
- 前記自己磁性有機分子に、細胞膜に結合親和性を有する疎水性分子が結合している、請求項5記載のドラッグデリバリー用キャリア化合物。
- 内部に薬剤を有する脂質膜と、当該脂質膜に、請求項1乃至6のいずれか1項に記載のドラッグデリバリー用キャリア化合物が結合している薬剤。
- 請求項7記載の薬剤を個体に適用後、外部磁場によって前記薬剤を目的の患部領域に誘導するドラッグデリバリーシステム。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011203497A JP5829871B2 (ja) | 2011-09-16 | 2011-09-16 | リポソーム薬剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011203497A JP5829871B2 (ja) | 2011-09-16 | 2011-09-16 | リポソーム薬剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013063926A true JP2013063926A (ja) | 2013-04-11 |
JP5829871B2 JP5829871B2 (ja) | 2015-12-09 |
Family
ID=48187796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011203497A Active JP5829871B2 (ja) | 2011-09-16 | 2011-09-16 | リポソーム薬剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5829871B2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170012369A (ko) | 2014-05-21 | 2017-02-02 | 소마아루 가부시끼가이샤 | N-아세틸글루코사민 당쇄기 함유 화합물, 약제 수송용 캐리어 화합물, 제제, 및 약제 수송 시스템 |
US11324831B2 (en) | 2014-11-13 | 2022-05-10 | Toagosei Co., Ltd | Method for introducing exogenous substance into cell, and material used in said method |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009173631A (ja) * | 2007-12-28 | 2009-08-06 | Ihi Corp | 鉄サレン錯体 |
JP2009274962A (ja) * | 2008-05-12 | 2009-11-26 | Yoshihiro Ishikawa | 鉄サレン錯体、磁性を有する薬剤、薬剤の誘導システム、並びに磁気検出装置 |
KR20100057382A (ko) * | 2008-11-21 | 2010-05-31 | 세종대학교산학협력단 | 살렌 전이금속 착화합물, 및 그 제조 방법 |
-
2011
- 2011-09-16 JP JP2011203497A patent/JP5829871B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009173631A (ja) * | 2007-12-28 | 2009-08-06 | Ihi Corp | 鉄サレン錯体 |
JP2009274962A (ja) * | 2008-05-12 | 2009-11-26 | Yoshihiro Ishikawa | 鉄サレン錯体、磁性を有する薬剤、薬剤の誘導システム、並びに磁気検出装置 |
KR20100057382A (ko) * | 2008-11-21 | 2010-05-31 | 세종대학교산학협력단 | 살렌 전이금속 착화합물, 및 그 제조 방법 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170012369A (ko) | 2014-05-21 | 2017-02-02 | 소마아루 가부시끼가이샤 | N-아세틸글루코사민 당쇄기 함유 화합물, 약제 수송용 캐리어 화합물, 제제, 및 약제 수송 시스템 |
US10471158B2 (en) | 2014-05-21 | 2019-11-12 | Somar Corporation | N-acetylglucosamine sugar chain group-containing compound, carrier compound for drug delivery, drug preparation, and drug delivery system |
US11324831B2 (en) | 2014-11-13 | 2022-05-10 | Toagosei Co., Ltd | Method for introducing exogenous substance into cell, and material used in said method |
Also Published As
Publication number | Publication date |
---|---|
JP5829871B2 (ja) | 2015-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Formulation of metal–organic framework-based drug carriers by controlled coordination of methoxy PEG phosphate: boosting colloidal stability and redispersibility | |
Graczyk et al. | Gold nanoparticles in conjunction with nucleic acids as a modern molecular system for cellular delivery | |
Pranantyo et al. | Antimicrobial peptide-reduced gold nanoclusters with charge-reversal moieties for bacterial targeting and imaging | |
Wang et al. | DNA-functionalized metal–organic framework nanoparticles for intracellular delivery of proteins | |
Freund et al. | Multifunctional efficiency: extending the concept of atom economy to functional nanomaterials | |
Zheng et al. | One-pot synthesis of metal–organic frameworks with encapsulated target molecules and their applications for controlled drug delivery | |
Pramanik et al. | Affimer tagged cubosomes: Targeting of carcinoembryonic antigen expressing colorectal cancer cells using in vitro and in vivo models | |
Nowinski et al. | Biologically inspired stealth peptide-capped gold nanoparticles | |
Nasrolahi Shirazi et al. | Cyclic peptide–selenium nanoparticles as drug transporters | |
Kulkarni et al. | Hypoxia responsive, tumor penetrating lipid nanoparticles for delivery of chemotherapeutics to pancreatic cancer cell spheroids | |
Choi et al. | Dendrimer-based multivalent vancomycin nanoplatform for targeting the drug-resistant bacterial surface | |
Kumar et al. | Covalently dye-linked, surface-controlled, and bioconjugated organically modified silica nanoparticles as targeted probes for optical imaging | |
Ojea-Jiménez et al. | Facile preparation of cationic gold nanoparticle-bioconjugates for cell penetration and nuclear targeting | |
Zhang et al. | Tumor acidic microenvironment targeted drug delivery based on pHLIP-modified mesoporous organosilica nanoparticles | |
Shi et al. | Synthetic DNA for Cell‐Surface Engineering | |
Fan et al. | Sequence-dependent peptide surface functionalization of metal–organic frameworks | |
Chen et al. | Subcellular fate of a fluorescent cholesterol-poly (ethylene glycol) conjugate: An excellent plasma membrane imaging reagent | |
Müller-Schiffmann et al. | Hybrid compounds: from simple combinations to nanomachines | |
Ye et al. | High-yield synthesis of monomeric LMWP (CPP)-siRNA covalent conjugate for effective cytosolic delivery of siRNA | |
Peng et al. | DNA nanostructure-programmed cell entry via corner angle-mediated molecular interaction with membrane receptors | |
Baskar et al. | Gold nanoparticle mediated delivery of fungal asparaginase against cancer cells | |
Liu et al. | Targeted intracellular controlled drug delivery and tumor therapy through in situ forming Ag nanogates on mesoporous silica nanocontainers | |
Ding et al. | Improving tumor accumulation of aptamers by prolonged blood circulation | |
Li et al. | Enhanced cancer starvation therapy enabled by an autophagy inhibitors-encapsulated biomimetic ZIF-8 nanodrug: disrupting and harnessing dual pro-survival autophagic responses | |
Durymanov et al. | Cellular uptake, intracellular trafficking, and stability of biocompatible metal-organic framework (MOF) particles in Kupffer cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140421 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150113 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150311 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150728 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150828 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150929 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151023 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5829871 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |